Home » Newsletters » BioWorld Science

BioWorld Science

May 19, 2011

View Archived Issues

Finasteride reduces priapism in young males with sickle cell disease

Updated preclinical and clinical data presented on antiviral CMX-001

Scientists at Eiger BioPharmaceuticals prepare new azaindazoles for HCV infections

Novel protein kinase inhibitors disclosed

Neuropeptide Y2 receptor agonists described by Roche as useful for metabolic disorders

JNJ-37822681 shows efficacy and promising metabolic profile in phase II trial in schizophrenia

Nizatidine improves symptoms of functional dyspepsia

Tofacitinib is efficacious in phase II trial in ulcerative colitis

RBM acquires biomarker research from Satoris for neurodegenerative disease testing

Tekmira and BMS expand research agreement to evaluate lipid nanoparticle formulations

Biomay's BM-32 vaccine enters phase I/II skin test trial in grass pollen allergy

New activators of soluble guanylate cyclase described

Enanta Pharmaceuticals discloses novel HCV protease inhibitors

University of Michigan presents new Smac mimetics with IAP-inhibiting activity

Takeda Pharmaceutical to acquire Nycomed

FDA approves Abbott's RealTime PCR molecular test for hepatitis C

NORD grants 2011 Corporate Award to Recordati for Carbaglu

Allon presents updated phase II/III data on davunetide in progressive supranuclear palsy

SuppreMol to in-license antibody against IL-3 for rheumatoid arthritis

Evotec and Roche terminate proof-of-concept trial of EVT-101 in depression

Synergy Pharmaceuticals advances GC-C agonist program for lowering cholesterol

WIBP and ProMetic Life Sciences expand strategic partnership agreement

Biothera initiates dosing in phase III trial of Imprime PGG with Erbitux

TxCell cleared to extend phase I/II trial of Ovasave in Crohn's disease

Enrollment begins in phase II TG-C trial in degenerative joint disease of the knee

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 8, 2026.
First measles treatment advances as vaccination rates drop
BioWorld
Scientists at the La Jolla Institute for Immunology have identified and characterized human antibodies that neutralize the measles virus by blocking its entry...
Infensa Bioscience identifies new ASIC blockers
BioWorld Science
Infensa Bioscience Pty Ltd. has patented new acid-sensing ion channel 1 (ASIC) blockers potentially useful for the treatment of stroke, among others.
Hantavirus is ‘sentinel’ more than acute pandemic threat
BioWorld
News of eight infections and three deaths so far due to an emerging zoonotic virus has brought back unhappy memories of the early days of SARS-CoV-2. At a press...
Kymera’s IRF5 degrader shows potential in IBD treatment
BioWorld Science
At the recently concluded Digestive Disease Week, researchers from Kymera Therapeutics Inc. presented preclinical efficacy data on KT-579, a selective oral IRF5...